After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Vera Therapeutics Inc is $3.30B. A total of 1.11 million shares were traded on the day, compared to an average of 1.53M shares.
In the most recent transaction, Turner William D. sold 10,000 shares of VERA for 50.08 per share on Dec 15 ’25. After the transaction, the Chief Regulatory Officer now owns 22,500 company shares. In a previous transaction on Dec 11 ’25, ENRIGHT PATRICK G bought 5,882 shares at 42.50 per share. VERA shares that Director owns now total 5,882.
Among the insiders who bought shares, WILLIAM TURNER acquired of 10,000 shares on Dec 15 ’25 at a per-share price of $49.80. In another insider transaction, Turner William D. sold 10,000 shares at $45.31 per share on Dec 08 ’25. Company shares held by the Chief Regulatory Officer now total 22,500.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, VERA has a high of $56.05 and a low of $18.53.
As of this writing, VERA has an earnings estimate of -$1.27 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$1.11 per share and a lower estimate of -$1.62. The company reported an EPS of -$0.72 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. VERA’s latest balance sheet shows that the firm has $79.67M in Cash & Short Term Investments as of fiscal 2021. There were $4.92M in debt and $7.69M in liabilities at the time. Its Book Value Per Share was $6.24, while its Total Shareholder’s Equity was $69.59M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VERA is Buy with a score of 4.60.
